Last reviewed · How we verify

NCT00029029

Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases

Completed Phase 2 Last updated 12 August 2020
What this trial tests

Phase 2 trial testing pain therapy in Metastatic Cancer. Completed in 24 October 2002.

Timeline
13 October 2000
Primary endpoint
24 October 2002
24 October 2002

Quick facts

Lead sponsorMayo Clinic
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Primary purposesupportive care
Start date13 October 2000
Primary completion24 October 2002
Estimated completion24 October 2002
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 120, any sex, with Metastatic Cancer or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells and may help to relieve pain caused by bone metastases. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in relieving pain in patients who have bone metastases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of pain therapy

Trials testing the same drug.

Other recruiting trials for Metastatic Cancer

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00029029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing